Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05541315 · ClinicalTrials.gov registry record · Phase 1
A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT05541315 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 40 participants.
The verdict
NCT05541315, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of a single oral dose of JNJ-88260237 in healthy participants
Interventions
- DRUG Placebo
- DRUG JNJ-88260237
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-09-14 |
| Est. Completion | 2023-05-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05541315
The ClinicalTrials.gov registry entry for NCT05541315 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05541315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05541315 about?
NCT05541315 is a clinical study titled "A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants". The purpose of this study is to assess the safety and tolerability of a single oral dose of JNJ-88260237 in healthy participants
What is the current status of trial NCT05541315?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2022-09-14. Estimated completion is 2023-05-09.
What interventions are being tested in trial NCT05541315?
The interventions under investigation include: Placebo (DRUG), JNJ-88260237 (DRUG).
Who is sponsoring clinical trial NCT05541315?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.